post-title portfolio-title Lomustine Hard Capsule IP 40mg Taj Pharma 2020-02-25 11:07:27 no no

Lomustine Hard Capsule IP 40mg Taj Pharma



Lomustine 40mg Capsule is used in the treatment of different kinds of cancers. It may be also used to treat other conditions, as determined by the doctor.

Lomustine 40mg Capsule should be taken on an empty stomach, but try to take it at the same time every day. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

The most common side effects of this medicine include nausea and vomiting. This medicine may reduce the number of blood cells in your blood thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with kidney, liver and heart function during treatment with this medicine. Inform your doctor if you observe signs of infections such as fever, chills, body ache or if you have unusual bruising or bleeding.

Before taking it, tell your doctor if you have liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your doctor know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.


  • Brain tumor
  • Lung cancer
  • Hodgkin?s disease
  • Malignant melanoma



  • Nausea
  • Vomiting
  • Stomatitis (Inflammation of the mouth)
  • Hair loss
  • Decreased white blood cell count


Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it. Lomustine 40mg Capsule is to be taken empty stomach.


Lomustine 40mg Capsule is an anti-cancer medication. It works by damaging the genetic material (DNA and RNA) of the cancer cells. This stops their growth and multiplication.




It is unsafe to consume alcohol with Lomustine 40mg Capsule.



Lomustine 40mg Capsule is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.



Information regarding the use of Lomustine 40mg Capsule during breastfeeding is not available. Please consult your doctor.



It is not known whether Lomustine 40mg Capsule alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.



Lomustine 40mg Capsule should be used with caution in patients with kidney disease. Dose adjustment of Lomustine 40mg Capsule may be needed. Please consult your doctor.
Regular monitoring of kidney function tests is advised while you are taking this medicine. Use of Lomustine 40mg Capsule is not recommended in patients with severe kidney disease.



There is limited information available on the use of Lomustine 40mg Capsule in patients with liver disease. Please consult your doctor.
However, regular monitoring of liver function tests is advised while you are taking this medicine.


If you miss a dose of Lomustine 40mg Capsule, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.

Lomustine Hard Capsule IP 40mg Taj Pharma


Lomustine Hard Capsules IP 40mg Taj Pharma


Each Hard Capsule contains:
Lomustine IP?????? 40mg
Excipients????? q.s.

For the full list of excipients, see section 6.1.


Hard capsule


4.1 Therapeutic indications

As palliative or supplementary treatment, usually in combination with radiotherapy and/or surgery as part of multiple drug regimens in:

– brain tumours (primary or metastatic)

– lung tumours (especially oat-cell carcinoma)

Hodgkin’s disease (resistant to conventional combination chemotherapy)

– malignant melanoma (metastatic)

Lomustinemay also be of value as second-line treatment in Non-Hodgkin’s lymphoma, myelomatosis, gastrointestinal tumours, carcinoma of the kidney, the testis, the ovary, the cervix uteri and the breast.

?4.2 Posology and method of administration



Lomustineis given by mouth. The recommended dose in patients with normally functioning bone marrow receiving Lomustineas their only chemotherapy is 120 ? 130 mg/m? as a single dose every six to eight weeks (or as a divided dose over 3 days, e.g. 40 mg/m?/day).

Dosage is reduced

– if Lomustineis given as part of a drug regimen which includes other marrow-depressant medicinal products.

– in the presence of leucopenia below 3,000/mm? or thrombocytopenia below 75,000/mm?.

Marrow depression after Lomustineis sustained longer than after nitrogen mustards and recovery of white cell and platelet counts may not occur for six weeks or more. Blood elements depressed below the above levels should be allowed to recover to 4,000/mm? (WBC) and 100,000/mm? (platelets) before repeating Lomustinedosage.

Paediatric population

Until further data is available, administration of Lomustineto children with malignancies other than brain tumours should be restricted to specialised centres and exceptional situations. Dosage in children, like that in adults, is based on body surface area (120 – 130 mg/m? every six to eight weeks, with the same qualifications as apply to adults).

Method of administration

Lomustineis given by mouth.

?4.3 Contraindications

Lomustine can cause birth defects. Men and women are recommended to take contraceptive precautions during therapy with lomustine and for 6 months after treatment. Men should be informed about the risk for an irreversible infertility due to treatment with lomustine (see section 4.6).

Lomustineshould not be administered to patients who are pregnant or to mothers who are breastfeeding.

Other contraindications are:

– Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1;

– Previous hypersensitivity to nitrosoureas;

– Previous failure of the tumour to respond to other nitrosoureas;

– Severe bone marrow depression;

– Severe renal impairment;

– Coeliac disease or wheat allergy;

– Concomitant use of yellow fever vaccine or other live vaccines is contraindicated in immunosuppressed patients (see section 4.5).

?4.4 Special warnings and precautions for use

Patients receiving Lomustinechemotherapy should be under the care of doctors experienced in cancer treatment. Delayed bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to bleeding and overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of lomustine.

Therefore, blood counts should be carried out before starting the medicinal product and at frequent intervals (preferably weekly for at least 6 weeks after a dose; see section 4.8) during treatment. Treatment and dosage is governed principally by the haemoglobin, white cell count and platelet count. Liver and kidney function should also be assessed periodically.

Patients must be strictly instructed not to use higher doses of lomustine than recommended by a physician and should be told that lomustine is taken as a single oral dose and will not be repeated for at least 6 weeks.

The bone marrow toxicity of lomustine is cumulative and therefore dose adjustments must be considered on the basis of nadir blood counts from prior dose.

Caution should be used in administering lomustine to patients with decreased circulating platelets, leukocytes, or erythrocytes.

Pulmonary toxicity from lomustine appears to be dose-related (see section 4.8). Baseline pulmonary function studies should be conducted along with frequent pulmonary function tests during treatment. Patients with a baseline below 70 % of the predicted Forced Vital Capacity (FVC) or Carbon Monoxide Diffusing Capacity (DLco) are particularly at risk.

Since lomustine may cause liver dysfunction, it is recommended that liver function tests be monitored periodically (see section 4.8).

Renal function tests should also be monitored periodically (see section 4.8).

Long term use of nitrosoureas has been reported to be possibly associated with the development of secondary malignancies.

Care must be taken whenever handling anticancer products. Steps should be taken to avoid exposure. This includes appropriate equipment, such as wearing gloves, and washing hands with soap and water after handling such products.

?4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

Lomustineuse in combination with theophylline or with the H2?receptor antagonist cimetidine may potentiate bone marrow toxicity. Cross-resistance with other nitrosoureas is usual, but cross-resistance with conventional alkylating agents is unusual.

Pretreatment with phenobarbital can lead to a reduced antitumour effect of lomustine due to an accelerated elimination caused by induction of microsomal liver enzymes.

There is increased risk of fatal systemic vaccinal disease with the use of yellow fever vaccine. Live vaccines are contraindicated in immunosuppressed patients (see section 4.3)

Co-administration of antiepileptic medicinal products and chemotherapeutic medicinal products including lomustine can lead to complications secondary to pharmacokinetic interaction between the medicinal products.

?4.6 Fertility, pregnancy and lactation


Lomustineis contraindicated during pregnancy (see section 4.3). Safe use in pregnancy has not been established. Animal studies have shown reproductive toxicity (see section 5.3). If this medicinal product is used during pregnancy, or if the patient becomes pregnant while taking (receiving) this medicinal product, the patient should be apprised of the potential hazard to the foetus. Women of childbearing potential should be advised to avoid becoming pregnant.


Lomustineis contraindicated during breastfeeding (see section 4.3). Due to the lipophilic nature of lomustine, it is likely to be excreted in human milk. As a risk to the nursing child potentially exists, a decision must be made whether to discontinue breastfeeding or to discontinue/abstain from Lomustinetherapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.


Lomustine can have a mutagenic effect. Men treated with lomustine are therefore advised not to father children during treatment and for up to 6 months afterwards, and to seek advice regarding sperm conservation before the start of treatment given the possibility of irreversible infertility caused by lomustine therapy.

?4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

Lomustinecapsules can impair the ability to drive and use machines, e.g. because of nausea and vomiting.

?4.8 Undesirable effects

The list is presented by system organ class and frequency

  • Very common (?1/10)
  • Common (?1/100 to <1/10)
  • Uncommon (?1/1,000 to <1/100)
  • Rare (?1/10,000 to <1/1,000)
  • Very rare (<1/10,000)
  • Not known (cannot be estimated from the available data).
System Organ ClassFrequencyMedDRA Term
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)Not knownAcute leukaemia, myelodysplastic syndrome
Blood and lymphatic system disordersVery commonLeukopenia
Not knownBone marrow failure, thrombocytopenia, anaemia
Nervous system disordersNot knownCoordination abnormal, disorientation, lethargy, dysarthria
Respiratory, thoracic and mediastinal disordersNot knownPulmonary fibrosis, lung infiltration
Gastrointestinal disordersNot knownNausea, vomiting, stomatitis
Hepatobiliary disordersNot knownTransaminases increased, blood bilirubin increased
Skin and subcutaneous tissue disordersNot knownAlopecia
Renal and urinary disordersNot knownRenal failure, azotaemia, renal atrophy, renal injury
InvestigationsNot knownBlood alkaline phosphatase increased

Blood and lymphatic system disorders

The principal adverse effect is marrow toxicity of a delayed or prolonged nature. It usually occurs four to six weeks after administration of the medicinal product and is dose-related. Thrombocytopenia appears about four weeks after a dose of Lomustineand lasts one or two weeks at a level around 80 – 100,000/mm?. Leucopenia appears after five to six weeks and persists for one or two weeks at about 4 – 5,000/mm?.

The haematological toxicity may be cumulative, leading to successively lower white cell and platelet counts with successive doses of the medicinal product. Approximately 65 % of patients receiving 130 mg/m? develop white blood cell counts below 5,000 WBC/mm?. Thirty-six percent developed white blood cell counts below 3,000/mm?. Thrombocytopenia is generally more severe than leukopenia. However, both may be dose-limiting toxicities.

The occurrence of acute leukaemia and bone marrow dysplasia have been reported in patients following long-term nitrosourea therapy.

Anaemia also occurs, but is less frequent and less severe than thrombocytopenia or leukopenia.

Gastrointestinal disorders

Nausea and vomiting usually occur four to six hours after a full single dose of Lomustineand last for 24 ? 48 hours, followed by anorexia for two or three days. The effects are less troublesome if the 6-weekly dose is divided into three doses given on each of the first three days of the six week period. Gastrointestinal tolerance is usually good, however, if prophylactic antiemetics are given (e.g. metoclopramide or chlorpromazine). Disorders of liver function have been reported commonly. They are mild in most cases. In rare cases a cholestatic jaundice occurs. Transient elevation of liver enzymes (SGOT, SGPT, LDH or alkaline phosphatase) are occasionally observed.

More rarely patients are troubled by stomatitis and diarrhoea.

Nervous system disorders

Mild neurological symptoms, like e.g. apathy, disorientation, confusion and stuttering can occur uncommonly in combination therapy with other antineoplastic medicinal products or radiation.

Respiratory, thoracic and mediastinal disorders

Interstitial pneumonia or lung fibrosis have been reported rarely.

Renal and urinary disorders

Renal failure, decrease in kidney size, and progressive azotaemia have been reported in single cases after prolonged treatment with lomustine and related nitrosoureas reaching a high cumulative total dose. Therefore it is recommended not to exceed a maximum cumulative total lomustine dose of 1,000 mg/m?.

Kidney damage has also been reported occasionally in patients receiving lower total doses.

Other side effects

Loss of scalp hair has been reported rarely.

In single cases an irreversible vision loss has been reported after a combined therapy of lomustine with radiation.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

?4.9 Overdose


Accidental overdose with lomustine has been reported, including fatal cases. Symptoms of overdose with Lomustinewill probably include bone marrow toxicity, haematological toxicity, abdominal pain, nausea and vomiting, diarrhoea, anorexia, lethargy, dizziness, abnormal hepatic function, cough, and shortness of breath.

Emergency procedures

Overdose should be treated immediately by gastric lavage.


There is no specific antidote to overdose with Lomustine “medac”. Treatment should be symptomatic and supportive. Appropriate blood product replacement should be given as clinically required.


5.1 Pharmacodynamic properties

Pharmacotherapeutic group: cytostatics, alkylating agents,

The mode of action is believed to be partly as an alkylating agent and partly by inhibition of several steps in the synthesis of nucleic acid and inhibition of the repair of single strand breaks in DNA chains.

?5.2 Pharmacokinetic properties

Lomustineis readily absorbed from the intestinal tract. A maximum plasma concentration of 0.5 ? 2 ng/ml is reached after 3 hours following an oral dose of 30 ? 100 mg/m?.

The plasma disappearance of the chloroethyl-group follows by a single phased course with a half-life of 72 hours. The cyclohexyl-group disappears according to a twofold plasma disappearance with half-lives of 4 hours (t ? ?) and 50 hours (t ? ?). After oral application of radioactive marked lomustine the blood-brain-barrier is passed. Approximately 15 to 30 % of the measured radioactivity in the plasma can be detected in the cerebrospinal fluid.

Lomustineis rapidly metabolised and metabolites are excreted mainly via the kidneys. Lomustinecannot be detected in its active form in the urine at any time.

?5.3 Preclinical safety data

Lomustine is embryotoxic and teratogenic in rats and embryotoxic in rabbits at dose levels equivalent to the human dose.


6.1 List of excipients

Capsule contents:
Wheat Starch
Magnesium Stearate

Capsule shell:
Indigo carmine
Titanium Dioxide

?6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years as packaged for sale.

?6.4 Special precautions for storage

Do not store above 25 ?C.

Store in the original container in order to protect from light and moisture.

?6.5 Nature and contents of container

Securitainers containing 20 capsules.

?6.6 Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

?7. Manufactured in India By:
Mumbai, India
Survey No.188/1 to 189/1,190/1 to 4,
Athiyawad, Dabhel,
Daman- 396210 (INDIA)

Lomustine Capsules IP 40mg Taj Pharma
Package leaflet: Information for the patient


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section4.

What is in this leaflet:

  1. What Lomustine is and what it is used for
  2. What you need to know before you take Lomustine
  3. How to take Lomustine
  4. Possible side effects
  5. How to store Lomustine
  6. Contents of the pack and other information

This medicine contains an active ingredient called lomustine.

Lomustine belongs to a group of medicines called antineoplastic or cytotoxic agents. These medicines affect growth and proliferation of cancer cells.

Lomustine capsules are used to treat tumours and other malignant growths or diseases, for example, cancer of the lung or skin.


Do not take Lomustine
? if you are allergic to lomustine or any of the other ingredients of this medicine (listed in section?6).
? if you have had a similar medicine before which you had to stop taking because of side effects or because it was ineffective.
? if you have any blood disorder.
? if you have severe kidney problems.
? if you have coeliac disease (your body cannot digest gluten) or wheat allergy.
? if you have had a vaccination against yellow fever or another live vaccine vaccination and suffer from immunosuppression.
? if you are pregnant or breastfeeding.

You and your partner should avoid becoming pregnant or fathering a child during treatment and for at least 6?months after your treatment with lomustine has stopped.

Warnings and precautions
Talk to your doctor or pharmacist before taking Lomustine
? Do not take a higher dose of lomustine as prescribed by your doctor and do not repeat treatment before the end of 6?weeks.
? Your doctor will check your blood weekly during your therapy and up to 6?weeks afterwards.
? Lomustine might impair the function of your blood-building system, and increase the risk of bleeding and infections. This effect might occur after a certain time of therapy.
? As the toxic effects of lomustine to your bloodbuilding system are cumulative your doctor might decide to adjust the dosage of your therapy.
? Tell your doctor if you have any liver problems. Before you start with lomustine, your doctor will check the function of your liver and additionally of your lung and kidneys. These tests will be repeated during the time of your therapy.
? Long term use of nitrosoureas has been reported to be possibly associated with the development of secondary cancers.

Other medicines and Lomustine
No special studies regarding interactions between lomustine and other medicines have been performed, but tell your doctor if you are taking any of the following medicines:
? theophylline?? medicine used in the treatment of respiratory tract diseases, e.g.?asthma
? cimetidine?? medicine largely used in the treatment of heartburn and peptic ulcers
? other chemotherapeutic medicines, because co-administration can lead to complications due to interactions between the medicines.

Tell your doctor if you have ever taken phenobarbital?? an anticonvulsant, or any other antiepileptic medicine.

You should also inform your doctor if you have recently been vaccinated.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Pregnancy, breastfeeding and fertility
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Pregnant women should not take this medicine. It is important to tell your doctor if you are pregnant or think you might be pregnant, because safe use in pregnancy has not been established. If you become pregnant while you are treated with lomustine tell your doctor immediately, as taking lomustine might affect your unborn baby detrimentally. If you are of childbearing age you should avoid becoming pregnant.

You should not breast-feed your baby while being treated with this medicine, because lomustine might pass into your breast milk. As a risk to the nursing child potentially exists, a decision should be made whether to discontinue breast-feeding or to discontinue lomustine therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mother.

Men who are treated with lomustine should not father a child during their therapy and up to 6?month afterwards. As lomustine may affect your fertility, ask your doctor to inform you about possible precautions like sperm conservation before you start with the treatment.

Driving and using machines
No special studies have been performed, but Lomustine capsules can impair your ability to drive and use machines, e.g.?because of nausea and vomiting.

Lomustine contains lactose and wheat starch
This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

This medicine also contains wheat starch. Patients with wheat allergy or coeliac disease should not take this medicine (see above ?Do not take Lomustine?).


Care must be taken whenever handling anticancer products. Caution! Do not break open the Lomustine capsules. If you accidentally get the powder on your skin or in your mouth, wash it off with plenty of water. Wash your hands with soap and water after handling this product.

Always take this medicine exactly as your doctor has told you, and in an interval of no less than 6?weeks. Check with your doctor or pharmacist if you are not sure.

Lomustine capsules are taken by mouth. Swallow the capsules whole, do not chew or break them.

Use in adults
Your doctor will decide the exact dose to give you and how often to give it. Usually the dose depends on your height and weight. You may expect to receive 200???240?mg lomustine. Lomustine capsules are usually taken once every 6?to 8?weeks either as a single dose or as a divided dose over 3?days, e.g.?80?mg/day.

The dose you take may be reduced if you are taking other medicines to treat your condition or if you have a blood disorder.

Use in children
Lomustine capsules may be used in children with certain types of tumours. You must only use Lomustine for children as prescribed by the doctor. Lomustine capsules are usually taken once every 6?to 8?weeks either as a single dose or as a divided dose over 3?days, e.g.?40?mg/day.

If you take more Lomustine than you should
Accidental overdose with lomustine has been reported, including fatal cases. If you have taken too much medication please consult your doctor or local casualty department immediately.

An overdose might show in abdominal pain, diarrhoea, regurgitation, lack of appetite, lethargy, a feeling of dizziness, cough or shortness of breath.

If you forget to take Lomustine
It is important to complete the course of medication exactly as prescribed by your doctor. If you think you have missed a dose for any reason please tell your doctor or nurse immediately. Your doctor will decide how to proceed with the intake of Lomustine.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.


Like all medicines, this medicine can cause side effects, although not everybody gets them.

Please tell your doctor immediately if any of the following side effects occur:

Not known (frequency cannot be estimated from the available data)
? Various types of effects on the blood, such as too little red and white blood cells and/or platelets. This can manifest itself either in the fact that you bruise more easily than usual or you suffer repeated infections, e.g. sore throat or cough. You should contact your doctor immediately if this occurs.
? Nausea, vomiting and loss of appetite. Nausea and vomiting usually occur approximately 3?? 6?hours after you have taken your dose and can last for 24?? 48?hours, possibly followed by reduced appetite for 2?? 3?days. Your doctor may prescribe other medicines (anti-emetics) which you can take concurrently to relieve this. It might also help to take lomustine on an empty stomach.
? Stomatitis (inflammation inside the mouth) and diarrhoea
? Apathy, difficulties in orientation, confusion and stuttering
? Hair loss

Other possible side effects:

Very common (may affect more than 1 in 10 people)
? Decrease in white blood cells

Not known(frequency cannot be estimated from the available data)
? Acute leukaemia (blood cancer) and myelodysplastic syndrome (blood disorder associated with insufficient production of blood cells in the bone marrow)
? Pneumonia
? Acute and chronic lung reactions with changes in lung tissue seen in x-ray, shortness of breath and dry cough
? Lasting visual impairment (in combination with radiation treatment)
? Kidney failure, decrease in kidney size and kidney damage
? Abnormal coordination
? Sleepiness, sluggishness
? Difficulty speaking, unclear speech
? Increase in liver enzymes and bilirubin (breakdown product of the red blood pigment)

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.


Keep this medicine out of the sight and reach of children.

Do not store above 25??C.

Keep the box in the outer carton in order to protect from light and moisture.

Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. At the end of treatment return any leftover medicine to your hospital or pharmacist.


What Lomustine contains
– The active substance is lomustine.

Each Hard Capsule contains:
Lomustine IP?????? 40mg
Excipients????? q.s.

– The other ingredients are lactose, wheat starch, talc and magnesium stearate. The capsule is made of gelatine and the colouring agents titanium dioxide and indigotine.

Contents of the pack

Lomustine are blue hard capsules. Lomustine capsules are packed in a plastic box.
There are 20?capsules in each pack.

7. Manufactured in India By:
Mumbai, India
at SURVEY NO. 188/1, 190/1TO 4, ATHIYAWAD , DABHEL,
DAMAN- 396210 (INDIA)

What people say about our doctor?


More from Portfolio

  • Lomustine Hard Capsule IP 40mg Taj Pharma

    Lomustine Hard Capsule IP 40mg Taj Pharma Overview INTRODUCTION Lomustine 40mg Capsule is used in the treatment of different kinds of cancers. It may be also used to treat other conditions, as determined by the doctor. Lomustine 40mg Capsule should be taken on an empty stomach, but try to take it at the same time […]

  • Procarbazine Hydrochloride Capsules IP 50mg Taj Pharma

    Procarbazine Hydrochloride Capsules IP 50mg Taj Pharma Overview INTRODUCTION Procarbazine Hydrochloride 50mg Capsule is used in the treatment of some kinds of cancers. It may be also used to treat other conditions, as determined by the doctor. It is used with other medicines as part of combination chemotherapy to treat cancers such as Hodgkin?s disease […]

  • Irinotecan Injection IP 100mg/5ml (Iretrol-Taj) Taj Pharma

    Irinotecan Injection IP 100mg/5ml (Iretrol-Taj) Taj Pharma Overview Introduction of Iretrol-Taj Injection Iretrol-Taj 20 mg Injection is used in the treatment of cancer of colon and rectum. Iretrol-Taj 20 mg Injection is given as an injection by a qualified medical professional. It is taken in a dose as recommended by the doctor. You should continue […]

  • Megestrol Acetate Tablets IP?160mg Taj Pharma

    Megestrol Acetate Tablets IP? 160mg Taj Pharma Overview INTRODUCTION Megestrol Acetate 160 Tablet is used to treat breast cancer and endometrial cancer. It specifically helps treat breast and endometrial cancer that are hormone dependent. It may also be used for treating low appetite and weight loss in patients with advanced cancer or HIV. Megestrol Acetate […]

Latest News on Your Doctor's Blog